English

Ratos invests in Dynal Biotech

Report this content
Ratos has agreed with Nordic Capital to acquire 25% of the Norwegian biotech company Dynal Biotech. The investment will not be completed until customary conditions have been fulfilled and regulatory approvals in Norway have been obtained, which is expected to occur in August.

- By this co-operation with Nordic Capital, Ratos gets the opportunity to invest in the biotech industry, in which we see exciting opportunities. We particularly value Dynal Biotech's position with a well-established and profitable base business within separation of biological substances. In addition to this, we see interesting potential in the research and development activities of the company, says Arne Karlsson, CEO of Ratos.

Dynal Biotech (www.dynalbiotech.com) is world leading within research, development and production of magnetic and non-magnetic very small completely spherical polymer beads, and markets a wide range of products based on its technology. Among the applications is separation of biological substances. The company has customers and partners within industry as well as research, mainly in the diagnostics, genomics and cell therapy sectors. Dynal's main site is in Oslo. Its products are sold through subsidiaries and distributors in more than 30 countries. In 2000, it had a turnover of NOK 353m. The company employs approximately 230 people.


For further information please contact:
Arne Karlsson, CEO, +46 703 79 79 79

Subscribe